Feb 13 (Reuters) - KalVista Pharmaceuticals said on Tuesday its therapy for a type of skin condition met the main goals in a late-stage trial. (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.86 USD | -0.17% | -4.80% | -2.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.94% | 501M | |
-3.15% | 89.69B | |
+3.95% | 41.34B | |
-12.12% | 33.72B | |
+61.34% | 26.11B | |
-20.31% | 14.63B | |
-8.78% | 12.84B | |
-11.46% | 11.66B | |
-43.05% | 11.52B | |
+4.12% | 8.92B |
- Stock Market
- Equities
- KALV Stock
- News KalVista Pharmaceuticals, Inc.
- KalVista meets main goals in late-stage trial for skin condition treatment